RNAseq of A375 melanoma cells and A375 with ARID1A KO in control conditions and treatment with trametinib, vemurafenib or combination
The experiment aimed to study mechanisms of melanoma drug resistance. ARID1A confers resistance to trametinib and therefore RNAseq was collected alongside other omics data for parental A375 likes, and A375 lines with ARID1A KO, in the presence of no drug, trametinib, vemurafenib or their combination